Thursday, September 17, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1ozempicwegovyzepboundglp-1

CBS News examines common misconceptions about Ozempic, Wegovy, Zepbound

The report addresses what patients and the public most often get wrong about how GLP-1 medicines work.

MH
By Maren Holt · Senior Reporter, GLP-1
Sep 16 15:22 ETSource: CBS News

The wire

  1. 01CBS News published an explainer on widespread misunderstandings about GLP-1 drugs including Ozempic, Wegovy and Zepbound.
  2. 02Public confusion about GLP-1 mechanisms and expectations affects adherence and demand.
  3. 03The piece is educational and reports no new study findings.

From the source

What most people get wrong about GLP-1 drugs like Ozempic, Wegovy and Zepbound

Read at news.google.com